<https://rdf.molmedb.upol.cz/reference/ref3362> <http://purl.org/ontology/bibo/pmid> "26914985"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/method33>,
		<https://identifiers.org/molmedb/MM490632>;
	<http://purl.org/ontology/bibo/doi> "10.1021/acs.jmedchem.5b01865"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM490393>;
	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/dc/terms/BibliographicResource>;
	<http://purl.org/dc/terms/bibliographicCitation> "Martin LJ, Koegl M, Bader G, Cockcroft XL, Fedorov O, Fiegen D, Gerstberger T, Hofmann MH, Hohmann AF, Kessler D, Knapp S, Knesl P, Kornigg S, Müller S, Nar H, Rogers C, Rumpel K, Schaaf O, Steurer S, Tallant C, Vakoc CR, Zeeb M, Zoephel A, Pearson M, Boehmelt G, McConnell D.: Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor. J Med Chem, Volume 59 (10), 2016"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/interaction/membrane21> .
<https://rdf.molmedb.upol.cz/interaction/int1024260> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3362> .
<https://rdf.molmedb.upol.cz/interaction/int1023897> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref3362> .
